Answers are grounded in this paper and cite their sources.
AIM: To investigate the role of the -347G-->GA polymorphism in the progression of colorectal cancer (CRC). METHODS: We designed a case-control study based on a population of CRC patients in China and normal healthy controls with no history of tumors or inherited diseases. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analyses were used to genotype the variants, and immunohistochemical staining was performed to measure the expression of E-cadherin in different allele cases among the CRC patients and normal controls. RESULTS: The GA-allele (G/GA heterozygous and GA/GA homozygous) did not increase the risk of CRC compared with the G-allele (OR=1.232, 95% CI=0.898-1.691). However, the frequencies of the GA-allele were higher in poorly differentiated (P=0.002) and proximal (P=0.019) CRC patients than in normal controls. We also observed that E-cadherin expression was lower in poorly differentiated CRC patients than in well differentiated CRC patients (P=0.001). Furthermore, E-cadherin expression was lower for the GA-allele than for the G-allele (G/G heterozygous) in CRC patients (P=0.018). In contrast, there was no significant difference in E-cadherin expression for the G-allele and GA-allele in normal controls (P=0.292). CONCLUSION: The -347G-->GA promoter polymorphism in E-cadherin gene is associated with specific CRC features, and may be a prognostic factor rather than a susceptibility factor during the progression of CRC.
No takes yet. Share an insight, caveat, or question.
Zou et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: